Viberzi Should NOT Be Given to This 85-Year-Old Patient
I strongly recommend against prescribing Viberzi (eluxadoline) to this 85-year-old patient with chronic diarrhea. The FDA drug label explicitly warns that "people 65 years old and older have had an increased number of side effects, including serious side effects and stomach problems, while taking VIBERZI than people younger than 65 years old have had" 1.
Critical Age-Related Safety Concerns
Elderly patients (≥65 years) experience significantly higher rates of adverse events with Viberzi, including serious complications 1. While the 2022 AGA guidelines conditionally recommend eluxadoline for IBS-D 2, this recommendation is based on trials that did not specifically evaluate safety in the geriatric population at the level needed to establish safety in this age group.
Key Safety Issues in Elderly Patients:
- Increased serious adverse events compared to younger patients 1
- Higher risk of gastrointestinal complications including severe constipation that can lead to hospitalization 1
- Life-threatening pancreatitis risk, particularly within the first week of treatment (can occur after just 1-2 doses) 1
- Sphincter of Oddi spasm leading to hospitalization 1
Dosing Considerations IF Use Is Absolutely Necessary
Research suggests that if eluxadoline must be used in patients ≥65 years, the 75 mg dose is superior to 100 mg 3. The subgroup analysis showed that elderly patients had greater composite response rates, abdominal pain relief, and stool consistency improvement with 75 mg compared to 100 mg 3. However, this does not negate the overall increased risk profile.
Mandatory Pre-Treatment Screening
Before even considering Viberzi in ANY patient, you must verify the following absolute contraindications 1:
Contraindications (Any ONE of these prohibits use):
- No gallbladder (most critical - associated with fatal pancreatitis)
- Alcohol consumption >3 drinks/day or history of alcohol abuse/addiction
- History of pancreatitis or pancreatic disease
- Biliary duct obstruction or sphincter of Oddi dysfunction
- Severe liver impairment (Child-Pugh Class C)
- History of chronic or severe constipation
- Known or suspected bowel obstruction
- Previous hypersensitivity to eluxadoline
Diagnostic Clarification Required
The term "chronic diarrhea" is insufficient for prescribing Viberzi. The drug is FDA-approved specifically for IBS-D (irritable bowel syndrome with diarrhea), not generic chronic diarrhea 2, 1. The patient must meet Rome III criteria for IBS-D, which requires:
- Recurrent abdominal pain associated with diarrhea
- Average worst abdominal pain score ≥3 (on 0-10 scale)
- Average stool consistency ≥5.5 on Bristol Stool Form Scale
- Symptoms present for adequate duration
If this patient has chronic diarrhea from other causes (inflammatory bowel disease, bile acid diarrhea, microscopic colitis, malabsorption, etc.), Viberzi is not indicated and alternative treatments should be pursued.
Alternative Approach for This Patient
Given the unacceptable risk-benefit ratio in an 85-year-old, consider:
- Rifaximin - Better safety profile in elderly, particularly for IBS-D with bloating 2
- Loperamide - Safer opioid option for symptomatic diarrhea control in elderly
- Dietary modifications - Low FODMAP diet
- Bile acid sequestrants - If bile acid diarrhea is suspected (present in ~30% of IBS-D patients) 4
Common Pitfall to Avoid
Do not prescribe Viberzi for non-IBS chronic diarrhea. The drug's efficacy data are specific to IBS-D 2, and using it off-label in elderly patients with other causes of diarrhea exposes them to serious risks (pancreatitis, sphincter of Oddi spasm, severe constipation) without evidence of benefit.
The FDA's explicit warning about increased adverse events in patients ≥65 years, combined with the availability of safer alternatives, makes Viberzi a poor choice for this 85-year-old patient 1.